Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411110 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT02411110 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 131 participants.
The verdict
NCT02411110, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
Interventions
- COMBINATION_PRODUCT LiRIS®
- COMBINATION_PRODUCT LiRIS Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2015-05-21 |
| Est. Completion | 2017-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411110
The ClinicalTrials.gov registry entry for NCT02411110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LiRIS® is the first listed.
NCT02411110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02411110 about?
NCT02411110 is a clinical study titled "A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome". This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
What is the current status of trial NCT02411110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2015-05-21. Estimated completion is 2017-01-09.
What interventions are being tested in trial NCT02411110?
The interventions under investigation include: LiRIS® (COMBINATION_PRODUCT), LiRIS Placebo (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02411110?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.